YanAn Bicon Pharmaceutical Listed Company
Symbool: 002411.SZ
SHZ
0.62
CNYMarktprijs vandaag
-0.5881
Koers/Winst Verhouding
-0.0152
Koers/Winst Groei Verhouding
950.01M
MRK Kapitalisatie
- 0.00%
DIV Rendement
YanAn Bicon Pharmaceutical Listed Company (002411-SZ) Jaarrekeningen
Balans
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 3267.61 | 950.2 | 842.6 | 710.4 | |||||||||||||||||
balance-sheet.row.short-term-investments | 194.74 | 73.1 | -240.1 | -216.7 | |||||||||||||||||
balance-sheet.row.net-receivables | 19813.77 | 4260.2 | 5748.3 | 5945.8 | |||||||||||||||||
balance-sheet.row.inventory | 3740.51 | 788.2 | 978.6 | 763.9 | |||||||||||||||||
balance-sheet.row.other-current-assets | 319.4 | 76.3 | 106.9 | 85.1 | |||||||||||||||||
balance-sheet.row.total-current-assets | 27141.29 | 6074.9 | 7676.5 | 7505.3 | |||||||||||||||||
balance-sheet.row.property-plant-equipment-net | 18876.13 | 2910 | 6651.1 | 8593.4 | |||||||||||||||||
balance-sheet.row.goodwill | 6512.07 | 1614.7 | 1641.3 | 1641.3 | |||||||||||||||||
balance-sheet.row.intangible-assets | 2412.53 | 531 | 670.9 | 774.6 | |||||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 8924.59 | 2145.8 | 2312.2 | 2416 | |||||||||||||||||
balance-sheet.row.long-term-investments | -30.09 | -15 | 288.5 | 261.6 | |||||||||||||||||
balance-sheet.row.tax-assets | 2272.59 | 984.9 | 151.9 | 171.9 | |||||||||||||||||
balance-sheet.row.other-non-current-assets | 9353.57 | 2761.1 | 1643.1 | 259.3 | |||||||||||||||||
balance-sheet.row.total-non-current-assets | 39396.78 | 8786.7 | 11046.8 | 11702.2 | |||||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.total-assets | 66538.08 | 14861.6 | 18723.3 | 19207.4 | |||||||||||||||||
balance-sheet.row.account-payables | 7878.36 | 1892 | 2036.3 | 2142.7 | |||||||||||||||||
balance-sheet.row.short-term-debt | 10572.87 | 1553 | 4617.7 | 4005.3 | |||||||||||||||||
balance-sheet.row.tax-payables | 3673.99 | 1062.4 | 1031.9 | 779 | |||||||||||||||||
balance-sheet.row.long-term-debt-total | 2554.55 | 231.9 | 283.2 | 1084.8 | |||||||||||||||||
Deferred Revenue Non Current | 504.79 | 126.1 | 132.9 | 139.2 | |||||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 58 | - | - | - | |||||||||||||||||
balance-sheet.row.other-current-liab | 14694.58 | 4597 | 20.2 | 46.3 | |||||||||||||||||
balance-sheet.row.total-non-current-liabilities | 4284.47 | 656.7 | 727.6 | 1285.9 | |||||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.capital-lease-obligations | 55.85 | 12.6 | 29.9 | 19.3 | |||||||||||||||||
balance-sheet.row.total-liab | 37430.28 | 8698.7 | 10650.4 | 10276.4 | |||||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.common-stock | 7113.22 | 1778.3 | 1778.3 | 1778.3 | |||||||||||||||||
balance-sheet.row.retained-earnings | -1660.9 | -1317.7 | 247.4 | 1204.5 | |||||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 0 | 0 | 0 | |||||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 21853.18 | 5312.8 | 5601.3 | 5522.6 | |||||||||||||||||
balance-sheet.row.total-stockholders-equity | 27305.5 | 5773.3 | 7627 | 8505.5 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 66538.08 | 14861.6 | 18723.3 | 19207.4 | |||||||||||||||||
balance-sheet.row.minority-interest | 1802.3 | 389.5 | 446 | 425.6 | |||||||||||||||||
balance-sheet.row.total-equity | 29107.8 | 6162.9 | 8073 | 8931 | |||||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 66538.08 | - | - | - | |||||||||||||||||
Total Investments | 213.13 | 58.1 | 48.4 | 44.9 | |||||||||||||||||
balance-sheet.row.total-debt | 13127.42 | 1784.9 | 4900.9 | 5090.1 | |||||||||||||||||
balance-sheet.row.net-debt | 10006.06 | 907.8 | 4058.2 | 4379.7 |
Kasstroomoverzicht
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | -1560.63 | -1054.7 | -659.7 | -1054.3 | |||||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 350.1 | 403.3 | 338.9 | |||||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 2112.3 | -732.8 | -1104.2 | |||||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.inventory | 0 | -8.4 | -212.8 | -1.6 | |||||||||||||||||
cash-flows.row.account-payables | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.other-working-capital | 0 | 2120.8 | -520 | -1102.6 | |||||||||||||||||
cash-flows.row.other-non-cash-items | 0 | 1517.5 | 1590.6 | 1454.5 | |||||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | -1560.63 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | -1498.5 | -1452.8 | -281.1 | -143.7 | |||||||||||||||||
cash-flows.row.acquisitions-net | 1335.58 | 1335.6 | 0 | 0.1 | |||||||||||||||||
cash-flows.row.purchases-of-investments | -25.7 | -25.6 | 205.5 | -0.3 | |||||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0.01 | 996 | 3.8 | 0.7 | |||||||||||||||||
cash-flows.row.other-investing-activites | 985.62 | -10.3 | 132.8 | 1194.8 | |||||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 797.01 | 842.8 | 60.9 | 1051.7 | |||||||||||||||||
cash-flows.row.debt-repayment | -3769.74 | -3339 | -647.6 | -3023.1 | |||||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | 0 | 0 | |||||||||||||||||
cash-flows.row.dividends-paid | -2054.05 | -2021.4 | -200.1 | -431.2 | |||||||||||||||||
cash-flows.row.other-financing-activites | 2695.35 | 2222.5 | 460.1 | 2738.8 | |||||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | -3128.44 | -3137.9 | -387.6 | -715.5 | |||||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 23.75 | 23.7 | -1 | -0.4 | |||||||||||||||||
cash-flows.row.net-change-in-cash | -227.08 | 653.9 | 273.8 | -29.3 | |||||||||||||||||
cash-flows.row.cash-at-end-of-period | 2538.32 | 1154.2 | 500.7 | 226.8 | |||||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 2765.4 | 500.3 | 226.8 | 256.1 | |||||||||||||||||
cash-flows.row.operating-cash-flow | -1560.63 | 2925.3 | 601.4 | -365 | |||||||||||||||||
cash-flows.row.capital-expenditure | -1498.5 | -1452.8 | -281.1 | -143.7 | |||||||||||||||||
cash-flows.row.free-cash-flow | -3059.13 | 1472.4 | 320.3 | -508.8 |
Rij winst-en-verliesrekening
common:word.in-mln USD Growth | TTM | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 7057.74 | 8106.3 | 7663.2 | 6939.5 | |||||||||||||||||
income-statement-row.row.cost-of-revenue | 5817.12 | 6075.1 | 5311.9 | 5613.1 | |||||||||||||||||
income-statement-row.row.gross-profit | 1240.61 | 2031.2 | 2351.2 | 1326.4 | |||||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||||
income-statement-row.row.research-development | 127.63 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-general-administrative | 34.99 | - | - | - | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 290.11 | - | - | - | |||||||||||||||||
income-statement-row.row.other-expenses | 1153.16 | 1157.5 | 325.1 | 306.9 | |||||||||||||||||
income-statement-row.row.operating-expenses | 1605.89 | 1719.5 | 856.8 | 946.7 | |||||||||||||||||
income-statement-row.row.cost-and-expenses | 7423.02 | 7794.6 | 6168.7 | 6559.8 | |||||||||||||||||
income-statement-row.row.interest-income | -4.19 | -6 | 16 | 20.7 | |||||||||||||||||
income-statement-row.row.interest-expense | 201.51 | 283.7 | 357.9 | 1135.6 | |||||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 290.11 | - | - | - | |||||||||||||||||
income-statement-row.row.total-other-income-expensenet | -518.6 | -2001.5 | -1587.9 | -2048.9 | |||||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||||
income-statement-row.row.other-operating-expenses | 1153.16 | 1157.5 | 325.1 | 306.9 | |||||||||||||||||
income-statement-row.row.total-operating-expenses | -518.6 | -2001.5 | -1587.9 | -2048.9 | |||||||||||||||||
income-statement-row.row.interest-expense | 201.51 | 283.7 | 357.9 | 1135.6 | |||||||||||||||||
income-statement-row.row.depreciation-and-amortization | 1448.87 | 350.1 | 403.3 | 338.9 | |||||||||||||||||
income-statement-row.row.ebitda-caps | -271.28 | - | - | - | |||||||||||||||||
income-statement-row.row.operating-income | -1720.15 | 342.9 | 1219.9 | 930.6 | |||||||||||||||||
income-statement-row.row.income-before-tax | -2238.75 | -1658.6 | -368 | -1118.3 | |||||||||||||||||
income-statement-row.row.income-tax-expense | -692.52 | -603.9 | 291.7 | -45.5 | |||||||||||||||||
income-statement-row.row.net-income | -1560.63 | -1054.7 | -659.7 | -1072.8 |
Vaak gestelde vragen
Wat is YanAn Bicon Pharmaceutical Listed Company (002411.SZ) totale activa?
YanAn Bicon Pharmaceutical Listed Company (002411.SZ) totale activa is 14861598713.000.
Wat is de jaarlijkse omzet van de onderneming?
De jaarlijkse omzet is 3146759640.000.
Wat is de winstmarge van de onderneming?
De bedrijfswinstmarge is 0.155.
Wat is vrije kasstroom van de onderneming?
De vrije kasstroom is {free_cash_flow}}.
Wat is de nettowinstmarge van de onderneming?
De nettowinstmarge is -0.303.
Wat is de totale omzet van de onderneming?
De totale opbrengst is -0.342.
Wat is YanAn Bicon Pharmaceutical Listed Company (002411.SZ) nettowinst (netto-inkomen)?
De nettowinst is -1054699022.740.
Wat is de totale schuld van het bedrijf?
De totale schuld is 1784935683.000.
Wat zijn de bedrijfskosten?
De bedrijfsuitgaven zijn 1719493052.000.
Wat is het kasstroomcijfer van het bedrijf?
Enretprise cash is 489995625.000.